You need to be logged in to view this video
Steve O'Loughlin will present Actinium's leadership in the targeted radiotherapy field and how it is the only company pursuing well-validated targets in hematology with late-stage clinical programs. You will learn how the company's Iomab-B and Actimab-A programs have yielded promising clinical data in the relapsed/refractory Acute Myeloid Leukemia (AML). Finally, Mr. O'Loughlin will cover the company's investments in R&D, driving continued innovation in developing Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation.
Steve O'Loughlin is the chief financial officer of Actinium Pharmaceuticals, Inc., and joined Actinium in October 2015 as VP of finance and corporate development. He has nearly 15 years of life sciences industry experience. This experience is gained from previous positions in investment banking and publicly traded life sciences companies developing and commercializing therapeutics, diagnostics, and services.
Filter By Category
Filter By Keywords